GlassScriptPhysician profile
Chelsea Beiser
NPI 1497297394
$17,986.18
in general payments reported to CMS, 2019-2025
35 companies · $3,516 in 2025
The $3,516 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,230 · 2022: $3,262 · 2023: $3,892 · 2024: $4,086 · 2025: $3,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $810 · Education: $48.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,634.99 |
| Consulting Fee | $810.00 |
| Education | $48.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,854.40 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,756.54 | 2021-2025 | Entyvio, Gattex, Aralast |
| Janssen Biotech, INC. | $1,691.19 | 2021-2025 | Stelara, Tremfya, Remicade |
| Regeneron Healthcare Solutions, INC. | $1,600.10 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,425.35 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $822.21 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $681.90 | 2021-2024 | Zeposia |
| Pfizer INC. | $560.69 | 2021-2025 | |
| Madrigal Pharmaceuticals | $524.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $465.50 | 2021-2025 | Talicia, Aemcolo, Movantik |
| Ardelyx, INC. | $440.27 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $414.34 | 2021-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $404.80 | 2021-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $379.41 | 2021-2023 | |
| Lilly USA, LLC | $352.82 | 2024-2025 | Omvoh |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $327.16 | 2022-2024 | Stelara, Tremfya, Remicade |
| Genzyme Corporation | $324.70 | 2022-2025 | |
| Celltrion USA INC. | $311.02 | 2024-2025 | Vegzelma, Zymfentra |
| Vivus LLC | $286.46 | 2021-2025 | Pancreaze, Qsymia |
| E.R. Squibb & Sons, L.L.C. | $228.29 | 2021 | |
| Merck Sharp & Dohme LLC | $157.10 | 2021-2024 | Dificid |
| Aimmune Therapeutics, INC. | $137.37 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $136.05 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $125.91 | 2021-2023 | Rebyota, Clenpiq, Cimzia |
| Novo Nordisk INC | $123.42 | 2025 | Wegovy |
| Gilead Sciences, INC. | $121.50 | 2021-2023 | |
| Pharmacosmos Therapeutics INC. | $95.24 | 2023 | Monoferric |
| Exact Sciences Corporation | $57.69 | 2023 | Cologuard Collection Kit |
| Evoke Pharma, INC. | $55.68 | 2024-2025 | |
| Lucid Diagnostics INC. | $42.54 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.60 | 2023 | Ocaliva |
| Alnylam Pharmaceuticals INC. | $17.80 | 2021 | |
| Biocon Biologics INC | $16.64 | 2025 | Yesintek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.19 | 2023 | Cyltezo |
| Ethicon US, LLC | $14.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Beiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.